Zobrazeno 1 - 10
of 106
pro vyhledávání: ''
Publikováno v:
Molecular Cancer Research. 18:835-846
Through the use of an unbiased, genome-scale CRISPR modifier screen, we identified NF1 suppression as a mechanism of resistance to EGFR inhibition in NRAS/KRAS/BRAFV600-wild-type colorectal cancer cells. Reduced NF1 expression permitted sustained sig
Autor:
Thomas Roeder, Lia Burkhardt, Judith Bossen, Line Steen, Iris Bruchhaus, Karin Uliczka, Christine Fink, Mandy Mong-Quyen Mai, Roxana Pfefferkorn, Michael Spohn, Holger Heine
Publikováno v:
Molecular Cancer Therapeutics. 18:1659-1668
Lung cancer is the leading cause of cancer-associated mortality. Mutations in the EGFR gene are among the most important inducers of lung tumor development, but success of personalized therapies is still limited because of toxicity or developing resi
Autor:
Junji Tsurutani, Iori Taki-Takemoto, Kaori Nakatani, Motoi Ohba, Tohru Ohmori, Toshimitsu Yamaoka, Ken-Ichi Fujita, Daisuke Kamei, Satoru Arata, Shinichi Iwai, Sojiro Kusumoto
Publikováno v:
Molecular Cancer Therapeutics. 18:112-126
The critical T790M mutation in EGFR, which mediates resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKI; gefitinib, erlotinib, and afatinib), has facilitated the development of third-generation mutation-selective EGFR TKIs
Autor:
Daniela Meco, Nadia Trivieri, Anna Lasorella, Valentina Muto, Maurizio Martini, Marco Tartaglia, Matteo Lucchini, Alessandro Bruselles, Andrea Ciolfi, Massimo Caldarelli, Massimiliano Mirabella, Tiziana Servidei, Riccardo Riccardi, Roberta Morosetti
Publikováno v:
Cancer Research. 77:5860-5872
The basis for molecular and cellular heterogeneity in ependymomas of the central nervous system is not understood. This study suggests a basis for this phenomenon in the selection for mitogen-independent (MI) stem-like cells with impaired proliferati
Publikováno v:
Cancer Research. 81:419-419
Background Although studies have identified several clinicopathological factors that can predict the response to and survival on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), few studies have clearly demonstrated the effect
Autor:
Si-Yang Liu, Qing Zhou, Lan-Ying Gou, A. Li, Zhi-Hong Chen, Bin Gan, Hua-Jun Chen, Bin-Chao Wang, Jian Su, Chong-Rui Xu, Qi Zhang, Jin-Ji Yang, Zheng Wang, Xue-Ning Yang, Zhenfan Yang, Shannon Chuai, Han Han-Zhang, Zhen Wang, Zhi Xie, Wen-Zhao Zhong, Zhou Zhang, Yu Bai, Xu-Chao Zhang, Si-Pei Wu, Ben-Yuan Jiang, Hong-Fei Gao, Yi-Long Wu
Publikováno v:
Clinical Cancer Research. 23:4929-4937
Purpose: MET amplification, responsible for 20% of acquired resistance to EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non–small cell lung cancer (NSCLC), presents an attractive target. Numerous studies have conferred susceptibili
Autor:
Lukas C. Heukamp, William Pao, Helen Pasternack, Christian Becker, Kerstin Albus, Matthias Scheffler, Reinhard Buettner, Johannes M. Heuckmann, Alexandra Florin, Martin L. Sos, Andreas H. Scheel, Jana Fassunke, Martin Peifer, Thorsten Persigehl, Sabine Merkelbach-Bruse, Sebastian Michels, Marc Bos, Lynnette Fernandez-Cuesta, Janine Altmüller, Dennis Plenker, Jürgen Wolf, Lydia Meder, Sandra Ortiz-Cuaran, Johannes Berg, llona Dahmen, Michaela Angelika Ihle, Carina Heydt, Hongbin Ji, Rieke Fischer, Roman K. Thomas, Christian Müller, Peter Nuernberg, Sascha Ansén, Christine M. Lovly, Hans-Ulrich Schildhaus, Katharina König
Publikováno v:
Clinical Cancer Research. 22:4837-4847
Purpose: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686). Experimental Design: We analyzed tumor biopsies f
Autor:
Soo-Hwan Lee, Seo-Yoon Jeong, Min Hee Hong, Seok-Young Kim, Hye Ryun Kim, Byoung Chul Cho, Jiyeon Yun, Chae Won Park
Publikováno v:
Cancer Research. 80:5198-5198
Background: 1st generation (erlotinib & gefitinib), 2nd generation (afatinib), and 3rd generation (osimertinib) EGFR TKIs have marked efficacy in patient with EGFR-mutant NSCLC. Unfortunately, patients who show T790M (-) mutation after treated with 1
Publikováno v:
Cancer Research. 80:4490-4490
Objective: Lung cancer is one of the leading causes of cancer-related mortality in the world, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. With the emergence of epidermal growth factor receptor tyrosine k
Publikováno v:
Cancer Immunology Research. 8:B57-B57
Objective: Non-small cell lung cancer (NSCLC) patients with specific EGFR mutations benefited from the emergence of EGFR tyrosine kinase inhibitors (EGFR-TKIs). Unfortunately, almost all cases eventually recrudesced after a median of 10 months. Thera